XNAS · Healthcare · Medical Instruments & Supplies
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.06 | 0.00 | +100.00% | $141.2M | ✅ Beat | +3.57% | -9.19% | — |
| 2026-02-17 | Q4 2025 | -0.04 | 0.06 | +250.00% | $140.5M | ✅ Beat | +9.19% | -5.55% | -11.95% |
| 2025-10-29 |
| Q3 2025 |
| -0.11 |
| -0.01 |
| +90.91% |
| $134.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-29 | Q2 2025 | -0.16 | -0.02 | +87.50% | $136.1M | ✅ Beat | +10.31% | +18.31% | +17.30% |
| 2025-02-12 | Q4 2024 | -0.15 | -0.08 | +46.67% | $124.3M | ✅ Beat | -6.54% | -7.91% | -21.36% |
| 2024-10-29 | Q3 2024 | -0.19 | -0.17 | +10.53% | $115.9M | ✅ Beat | +18.35% | +20.52% | +22.87% |
| 2024-07-30 | Q2 2024 | -0.17 | -0.17 | +0.00% | $116.3M | ➖ Inline | -1.95% | -2.00% | +17.36% |
| 2024-05-01 | Q1 2024 | -0.23 | -0.25 | -8.70% | $108.9M | ❌ Miss | -10.26% | -16.44% | -8.97% |
Showing last 8 quarters.